Diagnostics Solutions Strategic Priorities
The field of oncology is evolving and increasing in complexity
Driving the need for novel diagnostic solutions
Active T cell
Oncology market
is rapidly evolving
New therapies and therapy
combinations emerging to
prolong patients' lives
Step 3
Dendritic cell
Step 2
+
Active T cell
Step 4
Blood vessel
Blood vessel
Lymph node
Step 5
Tumor microenvironment
Lymph node
Step 6
Step 7
Antigens
Step 1
5,000+ clinical trials
are now exploring the utility
of cancer immunotherapy
Growing understanding of the biological
complexity of immune oncology
XXX
New diagnostics and
digital tools are required
Innovation is needed to
identify optimal therapies
for individual patients
⚫ Multi-modal diagnostics
·
.
Clinical decision support
S18 4341 A1-2
63
83
RocheView entire presentation